A Trial of SHR0410 Injection in Postsurgical Pain Management

Sponsor
Jiangsu HengRui Medicine Co., Ltd. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05394402
Collaborator
(none)
108
1
3
2.8
38.2

Study Details

Study Description

Brief Summary

The study is being conducted to evaluate the efficacy, safety of SHR0410 Injection and to explore the reasonable of SHR0410 Injection for Pain Management after Orthopaedic Surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: SHR0410 Injection
  • Drug: Placebo for SHR0410 Injection
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
SHR0410 Injection compared with placeboSHR0410 Injection compared with placebo
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled , Evaluation of the Safety, Efficacy of SHR0410 Injection for Pain Management Following Orthopaedic Surgery
Actual Study Start Date :
Aug 9, 2022
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Nov 3, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: SHR0410 Injection High dose

Drug: SHR0410 Injection
SHR0410 Injection

Experimental: SHR0410 Injection Low dose

Drug: SHR0410 Injection
SHR0410 Injection

Placebo Comparator: Placebo for SHR0410 Injection

Drug: Placebo for SHR0410 Injection
SHR0410 Injection blank preparation

Outcome Measures

Primary Outcome Measures

  1. Usage of Morphine, Post Surgery [0 hour to 48 hours after IP administration]

    Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 48 hour period post IP administration

Secondary Outcome Measures

  1. Usage of Morphine, Post Surgery at other intervals [0 hour to 24 hours after IP administration ;24 hours to 48 hours after IP administration]

    Change in the amount of morphine use (in milligrams) by subjects in each treatment group for 0-24 hours after IP administration.Change in the amount of morphine use (in milligrams) by subjects in each treatment group for 4-48 hours after IP administration.

  2. the Sum of Pain Intensity Differences in Pain Score Over 6、12、24、48 、12-24、24-48 Hours under static condition [48-hours]

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Rating Scale (NRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NRS.

  3. the Sum of Pain Intensity Differences in Pain Score Over 6、12、24、48 、12-24、24-48 Hours under moving condition [48-hours]

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Rating Scale (NRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NRS.

  4. Time to First Dose of Rescue Analgesia [0 hour to 48 hours after IP administration]

    Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.

  5. Frequency of Doses of Rescue Analgesia Utilized Per Subject, total consumption of morphine Rescue Analgesia Utilized Per Subject [0 hour to 24 hours after IP administration ;24 hours to 48 hours after IP administration ;0 hour to 48 hours after IP administration]

    Rescue analgesia was available to subjects with inadequately controlled pain upon request.

  6. Total press times of PCA pump and effective press times of PCA pump [0 hour to 24 hours after IP administration ;24 hours to 48 hours after IP administration ;0 hour to 48 hours after IP administration]

    Read and record the press times and effective press times from PCA

  7. Proportion of subjects who did not receive Rescue Analgesia [0 hour to 24 hours after IP administration ;24 hours to 48 hours after IP administration ;0 hour to 48 hours after IP administration]

    Proportion of rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.

  8. Participant ' satisfaction score for analgesia treatment [48-hours]

    Participants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 0 to 10, with 0 representing dissatisfied and 10 representing very satisfied.

  9. Investigator satisfaction score for analgesia treatment [48-hours]

    Postoperative analgesia was evaluated by investigators. The scale ranges from 0 to 10, with 0 being dissatisfied and 10 being very satisfied

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Able and willing to provide a written informed consent;

  2. Subjects requiring elective general anesthesia orthopedic surgery;

  3. Male or female;

  4. Meet the body mass index standard;

  5. Conform to the ASA Physical Status Classification;

  6. Negative pregnancy test.

Exclusion Criteria:
  1. Subjects with a history of myocardial infarction or unstable angina pectoris;

  2. Subjects with atrioventricular block or cardiac insufficiency;

  3. Subjects with a history of malignancy ;

  4. Subjects with a history of stroke;

  5. Subjects with a history of mental illness;

  6. Subjects with a history of difficult airway;

  7. Random blood glucose ≥11.1mmol/L;

  8. Subjects with poor blood pressure control;

  9. Abnormal values in liver or renal function;

  10. Subject with a history of substance abuse and drug abuse;

  11. Allergic to drugs that may be used during the study;

  12. Use other drugs that affect the analgesic effect before randomization, and the time from the last use to randomization is shorter than 5 half-lives;

  13. Participated in clinical trials of other drugs (received experimental drugs);

  14. Other circumstances that the investigator judged inappropriate for participation in this clinical trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China 430022

Sponsors and Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier:
NCT05394402
Other Study ID Numbers:
  • SHR0410-202
First Posted:
May 27, 2022
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022